These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

636 related items for PubMed ID: 17270296

  • 1. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
    Bertrand ME, Remme WJ, Fox KM, Ferrari R, Simoons ML, EUROPA investigators.
    Int J Cardiol; 2007 Sep 14; 121(1):57-61. PubMed ID: 17270296
    [Abstract] [Full Text] [Related]

  • 2. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G, Nicolosi GL, Chiariello M, Ferrari R, Remme P, Tavazzi L.
    Ital Heart J; 2005 Nov 14; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease.
    Fox KM, Bertrand ME, Remme WJ, Ferrari R, Simoons ML, Deckers JW, EUROPA Investigators.
    Am Heart J; 2007 Apr 14; 153(4):629-35. PubMed ID: 17383303
    [Abstract] [Full Text] [Related]

  • 4. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
    Brugts JJ, Boersma E, Chonchol M, Deckers JW, Bertrand M, Remme WJ, Ferrari R, Fox K, Simoons ML, EUROPA Investigators.
    J Am Coll Cardiol; 2007 Nov 27; 50(22):2148-55. PubMed ID: 18036453
    [Abstract] [Full Text] [Related]

  • 5. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial.
    Ferrari R, Bertrand ME, Remme WJ, Simoons ML, Deckers JW, Fox KM.
    Expert Rev Cardiovasc Ther; 2007 Nov 27; 5(6):1037-46. PubMed ID: 18035919
    [Abstract] [Full Text] [Related]

  • 6. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
    Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML, EUROPA Investigators.
    Eur Heart J; 2005 Jul 27; 26(14):1369-78. PubMed ID: 15860521
    [Abstract] [Full Text] [Related]

  • 7. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
    Ferrari R, Papa K, Bernocchi P, Gimbatti OJ, Golcea SS, Bettini A, Ceconi C.
    Ital Heart J; 2005 Nov 27; 6 Suppl 7():24S-32S. PubMed ID: 16485514
    [Abstract] [Full Text] [Related]

  • 8. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.
    Brugts JJ, Ninomiya T, Boersma E, Remme WJ, Bertrand M, Ferrari R, Fox K, MacMahon S, Chalmers J, Simoons ML.
    Eur Heart J; 2009 Jun 27; 30(11):1385-94. PubMed ID: 19346520
    [Abstract] [Full Text] [Related]

  • 9. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study.
    Ferrari R, Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators.
    Arch Intern Med; 2006 Mar 27; 166(6):659-66. PubMed ID: 16567606
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N, Cucherat M, Thuillez C, Durand E, Kadri Z, Steg PG.
    Arch Intern Med; 2006 Apr 10; 166(7):787-96. PubMed ID: 16606817
    [Abstract] [Full Text] [Related]

  • 12. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk.
    Deckers JW, Goedhart DM, Boersma E, Briggs A, Bertrand M, Ferrari R, Remme WJ, Fox K, Simoons ML.
    Eur Heart J; 2006 Apr 10; 27(7):796-801. PubMed ID: 16497685
    [Abstract] [Full Text] [Related]

  • 13. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study.
    Bertrand ME, Ferrari R, Remme WJ, Simoons ML, Deckers JW, Fox KM, EUROPA Investigators.
    Am Heart J; 2010 May 10; 159(5):795-802. PubMed ID: 20435188
    [Abstract] [Full Text] [Related]

  • 14. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA).
    Fox KM, Henderson JR, Bertrand ME, Ferrari R, Remme WJ, Simoons ML.
    Eur Heart J; 1998 Sep 10; 19 Suppl J():J52-5. PubMed ID: 9796841
    [Abstract] [Full Text] [Related]

  • 15. The perindopril in elderly people with chronic heart failure (PEP-CHF) study.
    Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, PEP-CHF Investigators.
    Eur Heart J; 2006 Oct 10; 27(19):2338-45. PubMed ID: 16963472
    [Abstract] [Full Text] [Related]

  • 16. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.
    Teo KK, Mitchell LB, Pogue J, Bosch J, Dagenais G, Yusuf S, HOPE Investigators.
    Circulation; 2004 Sep 14; 110(11):1413-7. PubMed ID: 15353497
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effectiveness and tolerability of administration of granulocyte colony-stimulating factor on left ventricular function in patients with myocardial infarction: a meta-analysis of randomized controlled trials.
    Kang S, Yang Y, Li CJ, Gao R.
    Clin Ther; 2007 Nov 14; 29(11):2406-18. PubMed ID: 18158081
    [Abstract] [Full Text] [Related]

  • 19. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K, Ferrari R, Tendera M, Steg PG, Ford I, BEAUTIFUL Steering Committee.
    Am Heart J; 2006 Nov 14; 152(5):860-6. PubMed ID: 17070146
    [Abstract] [Full Text] [Related]

  • 20. Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?
    Fox K, Ferrari R, Yusuf S, Borer JS.
    Eur Heart J; 2006 Sep 14; 27(18):2154-7. PubMed ID: 16905555
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.